Autoantibodies against aldehyde-modified collagen type IV are associated with risk of development of myocardial infarction
© 2017 The Association for the Publication of the Journal of Internal Medicine..
BACKGROUND: Oxidation of LDL particles entrapped in the extracellular matrix of the arterial wall is a key factor in the development of atherosclerosis. Lipid oxidation products, such as malondialdehyde (MDA), react with surrounding extracellular matrix proteins and cause modifications that are recognized by the immune system. MDA modification of collagen type IV is increased in carotid lesions from symptomatic patients and correlates with autoantibodies against MDA-modified collagen type IV in plasma.
OBJECTIVE: The aim of this study was to determine whether autoantibodies against MDA-modified collagen type IV predict risk of development of myocardial infarction (MI).
METHODS: Plasma levels of MDA-modified collagen type IV IgM and IgG antibodies were analysed by enzyme-linked immunosorbent assay in 385 subjects with incident MI during 13 years of follow-up and 410 age- and sex-matched controls in the Malmö Diet and Cancer study.
RESULTS: MDA-modified collagen type IV IgG levels were higher in cases with incident MI than in controls. Subjects in the highest tertile of MDA-modified collagen type IV IgG had an increased risk of MI (hazard ratio 1.56, 95% confidence interval 1.22-2.00, P for trend 0.0004). This association remained significant after adjusting for factors included in the Framingham risk score and diabetes. High levels of MDA-collagen type IV IgG were associated with increased carotid intima-media thickness and elevated plasma levels of matrix metalloproteinase 10 and 12.
CONCLUSIONS: Immune responses against MDA-modified collagen type IV are associated with more severe carotid disease and increased risk of MI. These immune responses may reflect LDL oxidation in the artery wall, but could also affect the atherosclerotic disease process.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:282 |
|---|---|
| Enthalten in: |
Journal of internal medicine - 282(2017), 6 vom: 06. Dez., Seite 496-507 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vallejo, J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.12.2017 Date Revised 21.12.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/joim.12659 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM276147952 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM276147952 | ||
| 003 | DE-627 | ||
| 005 | 20231225011338.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/joim.12659 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0920.xml |
| 035 | |a (DE-627)NLM276147952 | ||
| 035 | |a (NLM)28944562 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vallejo, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Autoantibodies against aldehyde-modified collagen type IV are associated with risk of development of myocardial infarction |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2017 | ||
| 500 | |a Date Revised 21.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2017 The Association for the Publication of the Journal of Internal Medicine. | ||
| 520 | |a BACKGROUND: Oxidation of LDL particles entrapped in the extracellular matrix of the arterial wall is a key factor in the development of atherosclerosis. Lipid oxidation products, such as malondialdehyde (MDA), react with surrounding extracellular matrix proteins and cause modifications that are recognized by the immune system. MDA modification of collagen type IV is increased in carotid lesions from symptomatic patients and correlates with autoantibodies against MDA-modified collagen type IV in plasma | ||
| 520 | |a OBJECTIVE: The aim of this study was to determine whether autoantibodies against MDA-modified collagen type IV predict risk of development of myocardial infarction (MI) | ||
| 520 | |a METHODS: Plasma levels of MDA-modified collagen type IV IgM and IgG antibodies were analysed by enzyme-linked immunosorbent assay in 385 subjects with incident MI during 13 years of follow-up and 410 age- and sex-matched controls in the Malmö Diet and Cancer study | ||
| 520 | |a RESULTS: MDA-modified collagen type IV IgG levels were higher in cases with incident MI than in controls. Subjects in the highest tertile of MDA-modified collagen type IV IgG had an increased risk of MI (hazard ratio 1.56, 95% confidence interval 1.22-2.00, P for trend 0.0004). This association remained significant after adjusting for factors included in the Framingham risk score and diabetes. High levels of MDA-collagen type IV IgG were associated with increased carotid intima-media thickness and elevated plasma levels of matrix metalloproteinase 10 and 12 | ||
| 520 | |a CONCLUSIONS: Immune responses against MDA-modified collagen type IV are associated with more severe carotid disease and increased risk of MI. These immune responses may reflect LDL oxidation in the artery wall, but could also affect the atherosclerotic disease process | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a autoantibodies | |
| 650 | 4 | |a malondialdehyde | |
| 650 | 4 | |a myocardial infarction | |
| 650 | 7 | |a Aldehydes |2 NLM | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Collagen Type IV |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 650 | 7 | |a Lipoproteins, LDL |2 NLM | |
| 650 | 7 | |a Procollagen |2 NLM | |
| 650 | 7 | |a Matrix Metalloproteinase 10 |2 NLM | |
| 650 | 7 | |a EC 3.4.24.22 |2 NLM | |
| 650 | 7 | |a Matrix Metalloproteinase 12 |2 NLM | |
| 650 | 7 | |a EC 3.4.24.65 |2 NLM | |
| 700 | 1 | |a Dunér, P |e verfasserin |4 aut | |
| 700 | 1 | |a Fredrikson, G N |e verfasserin |4 aut | |
| 700 | 1 | |a Nilsson, J |e verfasserin |4 aut | |
| 700 | 1 | |a Bengtsson, E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of internal medicine |d 1992 |g 282(2017), 6 vom: 06. Dez., Seite 496-507 |w (DE-627)NLM012608750 |x 1365-2796 |7 nnns |
| 773 | 1 | 8 | |g volume:282 |g year:2017 |g number:6 |g day:06 |g month:12 |g pages:496-507 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/joim.12659 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 282 |j 2017 |e 6 |b 06 |c 12 |h 496-507 | ||